title: In reply.
authors.affiliation: University of Toronto, Toronto, Ontario, Canada (W.S.B.). scott.beattie@uhn.ca.
authors.forename: Catherine
authors.initials: C
authors.lastname: Ashes
authors.forename: Saul
authors.initials: S
authors.lastname: Judelman
authors.forename: Duminda
authors.initials: D
authors.lastname: Wijeysundera
authors.forename: Gordon
authors.initials: G
authors.lastname: Tait
authors.forename: Gregory M T
authors.initials: GM
authors.lastname: Hare
authors.forename: C David
authors.initials: CD
authors.lastname: Mazer
authors.forename: W Scott
authors.initials: WS
authors.lastname: Beattie
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000009:adverse effects*; D001262:Atenolol / Q000009:adverse effects*; D017298:Bisoprolol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000009:adverse effects*; D011183:Postoperative Complications / Q000453:epidemiology*; D020521:Stroke / Q000453:epidemiology*
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D001262:Atenolol; D008790:Metoprolol; D017298:Bisoprolol